Oral Oncology
Volume 38, Issue 7 , Pages 680-685 , October 2002

Salivary gland hypofunction in patients with advanced cancer

  • Andrew N Davies

      Affiliations

    • Bristol Haematology and Oncology Centre, Horfield Road, Bristol BS2 8ED, UK
    • Corresponding Author InformationCorresponding author. Tel.: +44-117-928-3336; fax: +44-117-928-3865
    • ,
  • Karen Broadley

      Affiliations

    • Royal Marsden Hospital, Fulham Road, London SW3 6JJ, UK
    • ,
  • David Beighton

      Affiliations

    • Joint Microbiology Research Unit, GKT Dental Institute, Caldecot Road, London SE5 9RW, UK

Received 5 December 2001 ,Accepted 11 December 2001.

References 

  1. Navazesh M, Christensen C, Brightman V. Clinical criteria for the diagnosis of salivary gland hypofunction. J Dent Res. 1992;71:1363–1369
  2. Sreebny LM. Xerostomia: diagnosis, management and clinical complications. In:  Edgar WM,  O'Mullane DM editor. Saliva and oral health. 2nd ed. London: British Dental Association; 1996;p. 43–66
  3. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance, and the sensation of dry mouth in man. J Dent Res. 1987;66:648–653
  4. Pankhurst CL, Smith EC, Rogers JO, Dunne SM, Jackson SHD, Procter G. Diagnosis and management of the dry mouth (part 1). Dent Update. 1996;23:56–62
  5. Maltoni M, Pirovano M, Scarpi E, Marinari M, Indelli M, Arnoldi E, et al.  Prediction of survival of patients terminally ill with cancer. Cancer. 1995;75:2613–2622
  6. Jobbins J, Bagg J, Finlay IG, Addy M, Newcombe RG. Oral and dental disease in terminally ill cancer patients. Br Med J. 1992;304:1612
  7. Finlay IG. Oral symptoms and candida in the terminally ill. Br Med J. 1986;292:592–593
  8. Reuben DB, Mor V, Hiris J. Clinical symptoms and length of survival in patients with terminal cancer. Arch Intern Med. 1988;148:1586–1591
  9. Conill C, Verger E, Henriquez I, Saiz N, Espier M, Lugo F, et al.  Symptom prevalence in the last week of life. J Pain Symptom Manage. 1997;14:328–331
  10. Dunlop GM. A study of the relative frequency and importance of gastrointestinal symptoms, and weakness in patients with far advanced cancer (student paper). Palliat Med. 1989;4:37–43
  11. Ventafridda V, De Conno F, Ripamonti C, Gamba A, Tamburini M. Quality-of-life assessment during a palliative care programme. Ann Oncol. 1990;1:415–420
  12. Curtis EB, Krech R, Walsh TD. Common symptoms in patients with advanced cancer. J Palliat Care. 1991;7:25–29
  13. Osoba D, MacDonald N. Principles governing the use of cancer chemotherapy in palliative care. In:  Doyle D,  Hanks GW,  MacDonald N editor. Oxford Textbook of Palliative Medicine. 2nd ed. Oxford: Oxford University Press; 1998;p. 255
  14. Portenoy RK, Thaler HT, Kornblith AB, McCarthy Lepore J, Friedlander-Klar H, Kiyasu E, et al.  The Memorial Symptom Assessment Scale (an instrument for the evaluation of symptom prevalence, characteristics and distress). Eur J Cancer. 1994;30(A):1326–1336
  15. Anonymous . Saliva: its role in health and disease. FDI Working Group 10 of the Commission on Oral Health, Research and Epidemiology (CORE). Int Dent J. 1992;42(Suppl. 2):291–304
  16. Sreebny LM, Schwartz SS. A reference guide to drugs and dry mouth—2nd ed. Gerodontol. 1997;14:33–47
  17. Sweeney MP, Bagg J, Baxter WP, Aitchison TC. Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol. 1998;34:123–126
  18. Chaushu G, Bercovici M, Dori S, Waller A, Taicher S, Kronenberg J, et al.  Salivary flow and its relation with oral symptoms in terminally ill patients. Cancer. 2000;88:984–987
  19. Twycross RG, Lack SA. Control of alimentary symptoms in far advanced cancer. Edinburgh: Churchill Livingstone; 1986;
  20. Sreebny LM, Valdini A, Yu A. Xerostomia. Part II: relationship to nonoral symptoms, drugs, and diseases. Oral Surg Oral Med Oral Pathol. 1989;68:419–427
  21. Smith RG, Burtner AP. Oral side-effects of the most frequently prescribed drugs. Spec Care Dentist. 1994;14:96–102
  22. Osterberg T, Landahl S, Hedegard B. Salivary flow, saliva, pH and buffering capacity in 70-year-old men and women. J Oral Rehabil. 1984;11:157–170
  23. Wang SL, Zhao ZT, Li J, Zhu XZ, Dong H, Zhang YG. Investigation of the clinical value of total saliva flow rates. Arch Oral Biol. 1998;43:39–43
  24. Tabak LA, Levine MJ, Mandel ID, Ellison SA. Role of salivary mucins in the protection of the oral cavity. J Oral Pathol. 1982;11:1–17
  25. Davies AN. The management of xerostomia (a review). Eur J Cancer Care. 1997;6:209–214
  26. Davies AN, Singer J. A comparison of artificial saliva and pilocarpine in radiation induced xerostomia. J Laryngol Otol. 1994;108:663–665
  27. Rhodus NL, Liljemark W, Bloomquist C, Bereuter J. Candida albicans levels in patients with Sjogren's syndrome before and after long-term use of pilocarpine hydrochloride (a pilot study). Quintessence Int. 1998;29:705–710
  28. Weerkamp AH, Wagner K, Vissink A, s'-Gravenmade EJ. Effect of the application of a mucin-based saliva substitute on the oral microflora of xerostomic patients. J Oral Pathol. 1987;16:474–478

PII: S1368-8375(01)00133-6

Oral Oncology
Volume 38, Issue 7 , Pages 680-685 , October 2002

Article Tools

* Image Usage & Resolution